BioCentury
ARTICLE | Clinical News

Celgene, Acceleron planning submissions for luspatercept

June 28, 2018 10:58 PM UTC

Celgene Corp. (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) said luspatercept (ACE-536) met the primary endpoint in the Phase III MEDALIST trial to treat myelodysplastic syndrome (MDS). The partners plan to submit regulatory applications in the U.S. and Europe in 1H19 for the product in the indication.

Acceleron gained $11.02 (32%) to $45 in early after-hours trading Thursday. The companies announced the news after market close...